Worth Watching: What Next for Haemonetics Corporation Stock After Achieving 52-Week High?

Worth Watching: What Next for Haemonetics Corporation Stock After Achieving 52 Week High?

The stock of Haemonetics Corporation (NYSE:HAE) hit a new 52-week high and has $49.27 target or 30.00% above today’s $37.90 share price. The 6 months bullish chart indicates low risk for the $1.94 billion company. The 1-year high was reported on Nov, 8 by Barchart.com. If the $49.27 price target is reached, the company will be worth $582.00M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 81,034 shares traded hands. Haemonetics Corporation (NYSE:HAE) has declined 0.03% since April 5, 2016 and is downtrending. It has underperformed by 1.99% the S&P500.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Out of 7 analysts covering Haemonetics Corporation (NYSE:HAE), 2 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 29% are positive. $47 is the highest target while $28 is the lowest. The $36 average target is -5.01% below today’s ($37.9) stock price. Haemonetics Corporation has been the topic of 13 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Haemonetics Corporation (NYSE:HAE) earned “Hold” rating by Benchmark on Wednesday, May 11. The firm earned “Underperform” rating on Monday, November 23 by Raymond James. Jefferies maintained the stock with “Buy” rating in Tuesday, August 2 report. The rating was maintained by Barrington Research on Tuesday, October 6 with “Outperform”. As per Tuesday, July 28, the company rating was upgraded by Barrington Research. On Monday, August 15 the stock rating was downgraded by Sidoti to “Neutral”. On Thursday, November 5 the stock rating was maintained by Benchmark with “Hold”. The firm earned “Neutral” rating on Monday, May 16 by Goldman Sachs. The rating was maintained by Benchmark with “Hold” on Monday, November 7. The firm has “Market Perform” rating by CJS Securities given on Tuesday, September 20.

According to Zacks Investment Research, “Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections and plasma collections. The majority of their business is outside the US.”

Insitutional Activity: The institutional sentiment decreased to 1.55 in 2016 Q2. Its down 0.20, from 1.75 in 2016Q1. The ratio dived, as 18 funds sold all Haemonetics Corporation shares owned while 44 reduced positions. 31 funds bought stakes while 65 increased positions. They now own 50.62 million shares or 0.12% more from 50.56 million shares in 2016Q1.
First Personal Financial Ser, a North Carolina-based fund reported 53 shares. Airain Limited holds 0.06% or 34,856 shares in its portfolio. Tfs Cap Limited Liability Co accumulated 35,457 shares or 0.19% of the stock. Connor Clark & Lunn Invest Limited last reported 0% of its portfolio in the stock. Deutsche Comml Bank Ag has 272,675 shares for 0.01% of their US portfolio. Btim last reported 0.26% of its portfolio in the stock. Blackrock Inc owns 13,291 shares or 0% of their US portfolio. Rothschild Asset Management accumulated 86,106 shares or 0.05% of the stock. Moreover, Goldman Sachs Grp Inc has 0% invested in Haemonetics Corporation (NYSE:HAE) for 232,483 shares. New York State Teachers Retirement, a New York-based fund reported 101,326 shares. Huntington Commercial Bank, a Ohio-based fund reported 153 shares. D E Shaw Communication Inc last reported 0.01% of its portfolio in the stock. Capstone Asset Mngmt has 15,659 shares for 0.01% of their US portfolio. Century Cos last reported 0.01% of its portfolio in the stock. The Pennsylvania-based Stevens Cap Mngmt L P has invested 0.01% in Haemonetics Corporation (NYSE:HAE).

Insider Transactions: Since August 4, 2016, the stock had 1 insider purchase, and 2 insider sales for $1.43 million net activity. $2.10M worth of Haemonetics Corporation (NYSE:HAE) shares were bought by Simon – Christopher. $519,105 worth of Haemonetics Corporation (NYSE:HAE) was sold by FOOTE SUSAN BARTLETT on Friday, August 5. Another trade for 4,337 shares valued at $152,398 was sold by MERRIMAN RONALD.

Another recent and important Haemonetics Corporation (NYSE:HAE) news was published by Prnewswire.com which published an article titled: “Haemonetics Corporation Announces Christopher Simon as President and Chief …” on May 09, 2016.

HAE Company Profile

Haemonetics Corporation (Haemonetics), incorporated on August 29, 1985, is a healthcare company. The Firm provides various products to clients involved in the processing, handling and analysis of blood. The Company’s divisions include Japan, EMEA, North America Plasma and All Other. It provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. It provides analytical devices for measuring hemostasis, which enable healthcare providers to manage their patients’ bleeding risk. Haemonetics makes blood processing systems, and software, which tracks blood components. Haemonetics supplies systems and software, which facilitate blood transfusions and cell processing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment